Clinical-stage Potential Innovation Pharmaceuticals is a clinical-stage biopharma focusing on oncology, dermatology, and antimicrobial applications, presenting multiple near-term collaboration and licensing opportunities as their candidates advance in trials.

Defensin-mimetic Brilacidin Brilacidin, a defensin-mimetic with potential in skin infections, oral mucositis prevention during chemoradiation, and ulcerative proctitis, offers a diversified product profile for partnerships with large pharma or specialty firms in infectious disease and supportive cancer care.

Strategic Asset Portfolio Key assets Kevetrin, Prurisol, and Brilacidin cover cancer, psoriasis, and inflammatory/antimicrobial indications, enabling cross-disease licensing discussions and co-development opportunities with companies seeking a diversified oncology and dermatology pipeline.

Financial Leverage With sub-$1M revenue and a lean team, there is a clear path for strategic collaborations, milestone-driven deals, and upfront value creation through out-licensing or collaboration agreements with larger pharma players.

Digital & Brand Readiness Active online presence and modern tech stack (Squarespace, AWS, Cloudflare) support a professional lead generation and investor/partner outreach program, facilitating marketing, business development, and due diligence processes.